Total revenues (Tables)

12 Months Ended

Dec. 31, 2022

Total revenues

Revenue by collaboration and by category of revenue

	Over time	Point in time		2022		2021		2020
				(Euro, in		(Euro, in		(Euro, in
				thousands)		thousands)		thousands)
Recognition of non-refundable upfront payments and license fees			€	370,078	€	433,884	€	411,417
Gilead collaboration agreement for filgotinib	Ö			139,655		203,301		181,816
Gilead collaboration agreement for drug discovery platform	Ö			230,423		230,582		229,601
Milestone payments				36,777		32,408		46,261
Gilead collaboration agreement for filgotinib	Ö			34,777		32,408		46,261
Sobi distribution agreement for Jyseleca		Ö		2,000		-		-
Reimbursement income				56		-		4,073
Novartis collaboration agreement for MOR106	Ö			56		-		4,125
AbbVie collaboration agreement for CF	Ö			-		-		(52)
Royalties				10,770		3,801		16,300
Gilead royalties on Jyseleca		Ö		10,726		3,757		16,227
Other royalties		Ö		44		43		72
Total collaboration revenues			€	417,681	€	470,093	€	478,051

Summary of allocation of transaction price

	December 31, 2020		Other movements in 2021		Filgotinib amendment (September 6, 2021)		December 31, 2021		Other movements in 2022		December 31, 2022
Allocation of transaction price
Upfront consideration	€	4,005,373			€	12,643	€	4,018,016			€	4,018,016
Milestones achieved		194,363						194,363	€	18,238		212,601
Royalties		16,227	€	3,757				19,984		10,726		30,710
Impact initial valuation of share subscription		124,604						124,604				124,604
		4,340,567		3,757		12,643		4,356,967		28,964		4,385,931
Less :
Warrants issuance liabilities
Warrant A		(43,311)						(43,311)				(43,311)
Initial warrant B		(2,545)						(2,545)				(2,545)
Subsequent warrant B		(7,859)		5,417				(2,442)		1,714		(728)
		4,286,852		9,174		12,643		4,308,669		30,678		4,339,347
Allocation to performance obligations
Ziritaxestat		666,967						666,967				666,967
Filgotinib (1)		1,326,814		3,757	€	12,643		1,343,214		28,964		1,372,178
Drug discovery platform (10 years)	€	2,293,072	€	5,417			€	2,298,489	€	1,714	€	2,300,203
(1) With regard to the additional consideration received as a result of the Option, License and Collaboration agreement (July 14, 2019) allocated to the filgotinib performance obligation, we assumed the existence of a significant financing component estimated to €44.5 million as of December 31, 2019 reflecting the time value of money on the estimated recognition period. This financing component was reassessed to €55.3 million as of December 31, 2020, to €57.3 million on December 31, 2021 and to €58.7 million on December 31, 2022.